15 research outputs found
The impact of trust in healthcare and medication, and beliefs about medication on medication adherence in a Dutch medication-using population
INTRODUCTION: Trust in healthcare and medication, defined as feelings of reassurance and confidence in the healthcare system or medication, may be a key prerequisite before engaging in the use of medication. However, earlier studies have focussed on beliefs about medication rather than trust as predictors of medication adherence. This study therefore aims to simultaneously explore the relationship of trust in healthcare, medication and beliefs about medication, with medication adherence.METHODS: In a cross-sectional study, an online questionnaire was sent out to 1500 members of the Dutch Health Care Consumer Panel of Nivel in November 2018. Respondents were asked to grade their level of trust in healthcare and medication (scale 1-10). The Beliefs About Medicines Questionnaire (BMQ) for general and specific medication beliefs was used to address beliefs, the Medication Adherence Report Scale (MARS-5) to measure medication adherence. Data were analysed using structural equation modelling (SEM) with a backward stepwise approach. Out of 753 people that completed the questionnaire, 407 people used prescription medication and were included in the analyses.RESULTS: A positive association between trust in medication and medication adherence was found (0.044, p < 0.05). BMQ subscales Overuse (-0.083, p < 0.05), Necessity (0.075, p < 0.05) and Concerns (-0.134, p < 0.01) related with medication adherence. BMQ subscale Harm did not relate to medication adherence.CONCLUSION: Trust in medication and beliefs about medication were both individually associated with medication adherence. Healthcare providers should therefore not only focus on patients' medication beliefs, but also on strengthening patients' trust in medication to improve medication adherence.</p
Better use of inhaled medication in asthma and COPD through training, preparation and counselling:the On TRACk study protocol for a cluster randomised controlled trial
Introduction About 70% of patients with asthma and/or chronic obstructive pulmonary disease (COPD) use their inhaled medication incorrectly, leading to reduced disease control, higher healthcare use and costs. Adequate guidance from the pharmacy team from first dispense onwards can benefit patients in the long run. We propose an intervention ('On TRACk') to improve medication adherence and inhaler technique of adult patients with asthma and/or COPD. This intervention focuses on training pharmacy technicians (PTs) in patient-centred communication and inhalation instruction skills. In addition, patients are actively involved in refill consultations at the pharmacy. The aim of this study is to improve inhaler technique and better inhaled medication adherence among patients with asthma and/or COPD. This paper describes the study protocol. Methods and analysis A cluster randomised controlled trial (RCT) with an intervention and control group of 15 pharmacies each will be conducted. Per intervention pharmacy, two PTs will be trained online. Each PT will include five patients who will prepare their second and third dispense counselling sessions by selecting three topics they wish to discuss. Pharmacies in the control cluster provide usual care. In total, 300 patients (150 per group) will be included. Up to 12 months after inclusion, patients complete 3-monthly follow-up questionnaires. Both a process evaluation and a cost-effectiveness analysis will be performed alongside the trial. Trial effectiveness on the patient level will be evaluated after the 12-month follow-up period. Patient data will be collected through questionnaires and pharmacy refill data. Patients' inhaler technique will be visually assessed by PTs. Semistructured interviews with PTs and patients will be conducted regarding implementation and fidelity. Direct and indirect health costs will be collected to assess cost-effectiveness. The primary outcome is adherence to inhalation maintenance medication measured with pharmacy refill data. Secondary outcomes are inhaler technique, persistence, patients' attitudes towards medication, self-efficacy in medication use and communication with their PTs. Ethics and dissemination The study was approved by the Vrije Universiteit Amsterdam Ethics Committee (number: 2020.358). Results will be presented at (inter)national conferences and published in peer-reviewed journals. If proven to be (cost-)effective, the intervention should be considered for reimbursement and implementation in Dutch community pharmacies
ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΡΡΡΡΠΊΡΡΡΡ Π½Π° ΡΠ»Π΅ΠΊΡΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, ΠΌΠ΅ΠΆΡΠ°Π·Π½ΡΠΉ ΠΎΠ±ΠΌΠ΅Π½ ΠΈ Π΄ΠΈΡΡΡΠ·ΠΈΡ ΠΊΠΈΡΠ»ΠΎΡΠΎΠ΄Π° ΠΊΠ°ΡΠΎΠ΄Π½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² LSMβYSZ
Π Π°Π±ΠΎΡΠ° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΏΡΠΈ ΡΠΈΠ½Π°Π½ΡΠΎΠ²ΠΎΠΉ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠ΅ Π£ΡΠ€Π£ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π£ΡΠ€Π£ Π΄Π»Ρ ΠΏΠΎΠ±Π΅Π΄ΠΈΡΠ΅Π»Π΅ΠΉ ΠΊΠΎΠ½ΠΊΡΡΡΠ° Β«ΠΠΎΠ»ΠΎΠ΄ΡΠ΅ ΡΡΠ΅Π½ΡΠ΅ Π£ΡΠ€Π£Β»
Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a Randomised Controlled Trial to evaluate the effect of monitoring patients' medication use combined with short message service (SMS) reminders
Contains fulltext :
97026.pdf (publisher's version ) (Open Access)BACKGROUND: Innovative approaches are needed to support patients' adherence to drug therapy. The Real Time Medication Monitoring (RTMM) system offers real time monitoring of patients' medication use combined with short message service (SMS) reminders if patients forget to take their medication. This combination of monitoring and tailored reminders provides opportunities to improve adherence. This article describes the design of an intervention study aimed at evaluating the effect of RTMM on adherence to oral antidiabetics. METHODS/DESIGN: Randomised Controlled Trial (RCT) with two intervention arms and one control arm involving diabetes type 2 patients with suboptimal levels of adherence to oral antidiabetics (less than 80% based on pharmacy refill data). Patients in the first intervention arm use RTMM including SMS reminders and a personal webpage where they can monitor their medication use. Patients in the second intervention arm use RTMM without SMS reminders or webpage access. Patients in the control arm are not exposed to any intervention. Patients are randomly assigned to one of the three arms. The intervention lasts for six months. Pharmacy refill data of all patients are available from 11 months before, until 11 months after the start of the intervention. Primary outcome measure is adherence to oral antidiabetics calculated from: 1) data collected with RTMM, as a percentage of medication taken as prescribed, and as percentage of medication taken within the correct time interval, 2) refill data, taking the number of days for which oral antidiabetics are dispensed during the study period divided by the total number of days of the study period. Differences in adherence between the intervention groups and control group are studied using refill data. Differences in adherence between the two intervention groups are studied using RTMM data. DISCUSSION: The intervention described in this article consists of providing RTMM to patients with suboptimal adherence levels. This system combines real time monitoring of medication use with SMS reminders if medication is forgotten. If RTMM proves to be effective, it can be considered for use in various patient populations to support patients with their medication use and improve their adherence. TRIAL REGISTRATION: Netherlands Trial Register NTR1882
Relationship between inhaled corticosteroids adherence, short-acting beta agonists use, exacerbations and self-reported asthma control
ABSTRACT:
Introduction
The relationship between inhaled corticosteroids (ICS) adherence, short-acting beta agonist (SABA) use, and asthma outcomes is complex.
Aim
To investigate these relationships in a Dutch asthma patient cohort.
Methods
Patients aged C 12 years diagnosed with asthma who received C 2 inhalation medication prescriptions in 2016 were selected from Nivel Primary Care Database. This database contains information about patient characteristics, GP consultations, diagnoses and prescriptions. Adherence to ICS (implementation operationalized as Continuous Measure of medication Availability), SABA use (number of prescriptions), exacerbations (operationalized as a short course oral corticosteroids with daily dose[ 20 mg) and self-reported asthma control (measured with the Asthma Control Questionnaire; ACQ) were computed. Multilevel logistic regression analyses were used to model associations between ICS adherence, SABA use, and asthma outcomes, controlling for age, sex, comorbidity, comedication and asthma severity.
Results
Prescription data of 13,756 patients were included. ICS adherence averaged 62%. About 31% of patients received C 2 SABA prescriptions, 13% of patients experienced C 1 exacerbations in 2016. Self-reported asthma control was available for a subsample of patients (n = 2,388); 51% reported controlled asthma (ACQ score \0.75). A higher number of SABA prescriptions was associated with a higher risk of exacerbations and a higher risk of uncontrolled asthma, but also with being adherent to ICS. ICS adherence was not clearly associated with exacerbations, whilst an ICS adherence of[ 50% was associated with controlled asthma.
Conclusion
Minimizing SABA use appears to be an important strategy in reducing exacerbations and improving self-reported asthma control
Relationship between inhaled corticosteroids adherence, short-acting beta agonists use, exacerbations and self-reported asthma control
Relationship between inhaled corticosteroids adherence, short-acting beta agonists use, exacerbations and self-reported asthma control
Relationship between inhaled corticosteroids adherence, short-acting beta agonists use, exacerbations and self-reported asthma control
Understanding relationships between asthma medication use and outcomes in a SABINA primary care database study
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their short-acting beta-agonist (SABA) to control symptoms, which may increase their risk of exacerbations and uncontrolled asthma. Our objective is to describe ICS adherence and SABA use among Dutch primary care patients with asthma, and how these are related to exacerbations and self-reported asthma control. Patients aged β₯12 years diagnosed with asthma who received β₯2 inhalation medication prescriptions in 2016 were selected from the Nivel Primary Care Database. ICS adherence (continuous measure of medication availability), SABA use (number of prescriptions), exacerbations (short courses of oral corticosteroids with daily dose β₯20 mg), and asthma control (self-reported with the Asthma Control Questionnaire; ACQ) were computed. Multilevel logistic regression analyses, to account for clustering of patients within practices, were used to model associations between ICS adherence, SABA use, and asthma outcomes. Prescription data of 13,756 patients were included. ICS adherence averaged 62% (SD: 32.7), 14% of patients received β₯3 SABA prescriptions, and 13% of patients experienced β₯1 exacerbation. Self-reported asthma control was available for 2183 patients of whom 51% reported controlled asthma (ACQ-5 score 90%). ICS adherence was not associated with exacerbations, whilst poor ICS adherence (β€50%) was associated with uncontrolled asthma. In conclusion, increased SABA use is an important and easily identifiable signal for general practitioners to discuss asthma self-management behavior with their patients